← Back to Search

Palliative + Standard Care for Acute Myeloid Leukemia

N/A

Recruiting

Led By Areej El-Jawahri, MD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing whether a palliative care team working with an oncology team will improve end-of-life outcomes and quality of life for AML patients receiving non-intensive therapy.

Who is the study for?

This trial is for English-speaking adults with acute myeloid leukemia (AML) who are undergoing non-intensive therapy, such as hypomethylating agents or targeted therapies. It's not for those on intensive chemo that needs long hospital stays, already in palliative care, getting only supportive care, or with major psychiatric illnesses.Check my eligibility

What is being tested?

The study is looking at how combining standard leukemia treatment with palliative care affects the quality of life and end-of-life outcomes for AML patients. The focus is on whether this team approach can improve patient well-being during treatment.See study design

What are the potential side effects?

Since the trial involves standard leukemia treatments and palliative care services rather than new medications, side effects may include typical reactions to current AML therapies and emotional impacts from discussing serious illness.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time from documentation of end-of-life care preferences to death

Secondary outcome measures

Compare Rate of hospitalization between the study arms

Compare quality of end-of-life care between the two study arms

Patient-report of discussing end-of-life care preferences based on an item from the perception of treatment and prognosis questionnaire

+5 more

Other outcome measures

Rate of chemotherapy administration

Rates of death in the hospital

caregiver-reported discussion of end-of-life care preferences as measured by the perception of treatment and prognosis questionnaire

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Collaborative palliative and oncology careExperimental Treatment2 Interventions

1st palliative care visit within 96 hours of randomization in the outpatient or hospital In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone During hospital admissions to MGH: At least twice weekly palliative care visits

Group II: Standard leukemia careActive Control1 Intervention

Palliative care consults only upon request Standard Leukemia care

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,928 Previous Clinical Trials

13,198,035 Total Patients Enrolled

Areej El-Jawahri, MDPrincipal InvestigatorMassachusetts General Hospital

18 Previous Clinical Trials

4,192 Total Patients Enrolled

Media Library

Standard Leukemia care Clinical Trial Eligibility Overview. Trial Name: NCT03310918 — N/A

Acute Myeloid Leukemia Research Study Groups: Collaborative palliative and oncology care, Standard leukemia care

Acute Myeloid Leukemia Clinical Trial 2023: Standard Leukemia care Highlights & Side Effects. Trial Name: NCT03310918 — N/A

Standard Leukemia care 2023 Treatment Timeline for Medical Study. Trial Name: NCT03310918 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for recruitment in this experiment currently?

"The records on clinicaltrials.gov declare that the trial is currently recruiting participants, with its posting date being October 31st 2017 and last update occurring on August 23rd 2022."

Answered by AI

How many individuals are being invited to participate in this trial?

"Affirmative. According to records found on clinicaltrials.gov, this research effort is actively recruiting participants; the trial was initially posted in October of 2017 and has since been revised on August 23rd 2022. Ultimately, 320 individuals must be enrolled from two distinct facilities."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Collaborative Palliative and Leukemia Care Model for Patients With AML Receiving Non-Intensive Therapy

El-Jawahri, Areej,M.D. 2017. "A Collaborative Palliative and Leukemia Care Model for Patients With AML Receiving Non-Intensive Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03310918.